Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Immune Checkpoint Blockade In Cancer Therapy.

M. Postow, M. Callahan, J. Wolchok
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.
This paper references
10.1073/pnas.0712237105
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
10.1186/2051-1426-2-19
Opportunistic infections in patients treated with immunotherapy for cancer
Chrisann Kyi (2014)
10.1084/JEM.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
10.1084/jem.20051776
Tissue expression of PD-L1 mediates peripheral T cell tolerance
M. Keir (2006)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1126/science.1131078
Reversal of the TCR Stop Signal by CTLA-4
H. Schneider (2006)
10.1200/JCO.2014.32.15_SUPPL.5010
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A. Amin (2014)
10.1007/s10637-014-0092-7
Kidney injuries related to ipilimumab
H. Izzedine (2014)
bined BRAF and MEK inhibition in melanoma with BRAF V 600 mutations
KT Flaherty (2012)
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
S. Demaria (2005)
10.1200/JCO.2014.56.2736
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
10.1084/JEM.190.3.355
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1016/j.jaad.2014.02.035
Ipilimumab in patients with cancer and the management of dermatologic adverse events.
M. Lacouture (2014)
10.1016/S0140-6736(14)60958-2
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
Exome sequencing reveals a genetic basis underlying clinical response to CTLA-4 blockade
A Snyder (2014)
10.1158/1078-0432.CCR-12-3080
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
C. Robert (2013)
10.1056/NEJMoa1210093
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)
10.1186/1479-5876-9-204
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
O. Hamid (2010)
10.1200/JCO.2012.41.6750
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
10.1016/S1470-2045(14)70189-5
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
10.1084/JEM.174.3.561
CTLA-4 is a second receptor for the B cell activation antigen B7
P. Linsley (1991)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1200/JCO.2014.32.15_SUPPL.5011
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
T. Powles (2014)
10.1038/nm1517
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
10.1158/1078-0432.CCR-13-3271
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
J. Taube (2014)
10.1016/j.imlet.2010.09.022
New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.
D. Fanoni (2011)
10.1002/cncr.27969
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab
J. Weber (2013)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
J. Weber (2013)
10.1158/1078-0432.CCR-07-4079
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
R. Berger (2008)
10.1177/1352458514549403
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
E. Gettings (2015)
10.1093/jnci/djq310
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
10.1089/cbr.2008.0607
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
D. Minor (2009)
10.1200/JCO.2014.32.15_SUPPL.3006
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
F. S. Hodi (2014)
10.1200/JCO.2014.32.15_SUPPL.3002
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
N. Segal (2014)
10.1200/JCO.2014.32.15_SUPPL.3010
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Geoffrey T. Gibney (2014)
10.1200/JCO.2012.47.7521
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
Nienke van Rooij (2013)
10.1002/j.1460-2075.1992.tb05481.x
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
10.1007/s00262-014-1545-8
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
E. Simeone (2014)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
10.1007/s00262-008-0642-y
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
A. D. Giacomo (2008)
10.1007/s00262-008-0627-x
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Ilyssa O. Gordon (2008)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1200/JCO.2013.51.4802
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
J. Weber (2013)
10.1016/S1470-2045(13)70551-5
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
J. Westin (2014)
10.1038/nrclinonc.2010.223
Immune parameters affecting the efficacy of chemotherapeutic regimens
L. Zitvogel (2011)
10.1097/CJI.0b013e31819aa40b
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
M. Akhtari (2009)
10.1007/s11102-009-0193-z
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
T. Dillard (2009)
AntiCTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer
T Dillard (2010)
10.2967/jnumed.109.070946
Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
A. Ribas (2010)
10.1093/jnci/djs629
Combining radiotherapy and cancer immunotherapy: a paradigm shift.
S. Formenti (2013)
10.1073/pnas.1110814108
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
J. Yuan (2011)
10.1093/annonc/mdr028
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S. Wilgenhof (2011)
10.1158/2326-6066.CIR-13-0020
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
D. Ng Tang (2013)
10.1038/nm730
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1097/01.CJI.0000178913.41256.06
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Blansfield (2005)
10.1056/NEJMoa1406498
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
10.1093/annonc/mdt027
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
J. Delyon (2013)
10.1056/NEJMoa1112824
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
10.1016/S1074-7613(00)80089-8
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
10.1158/1078-0432.CCR-12-2625
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
E. Lipson (2012)
10.1126/SCIENCE.291.5502.319
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
10.1158/1078-0432.CCR-13-2797
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad S Atefi (2014)
olumab ( anti - PD - 1 ; BMS - 936558 , ONO - 4538 ) in combination with sunitinib or pazopanib in patients ( pts ) with metastatic renal cell carcinoma ( mRCC )
SC Formenti (2014)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1056/NEJMc1302338
Hepatotoxicity with combination of vemurafenib and ipilimumab.
A. Ribas (2013)
10.1158/2326-6066.CIR-13-0082
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
C. Barker (2013)
10.1097/CMR.0b013e32835fb524
Ipilimumab-induced acute severe colitis treated by infliximab.
C. Pages (2013)
10.1158/2326-6066.CIR-13-0115
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
E. Golden (2013)
10.1007/s00262-011-1172-6
An immune-active tumor microenvironment favors clinical response to ipilimumab
R. Ji (2011)
10.1200/JCO.2012.44.6112
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
10.1073/pnas.162359999
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
J. Riley (2002)
10.1007/s00262-014-1607-y
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen (2014)
10.1200/JCO.2005.01.109
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Yervoy ( ipilimumab ) : Immune - mediated adverse reaction management guide
JS Weber
10.1084/JEM.183.6.2533
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
M. Krummel (1996)
10.1002/cncr.25639
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
B. Rini (2011)
10.1056/NEJMCPC1302332
Case 21-2013
Ryan J. Sullivan (2013)
10.1200/JCO.2013.52.1377
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
S. Hu-Lieskovan (2014)
10.1097/00002371-200411000-00008
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1093/annonc/mdu344.1
1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL).
H. Kluger (2014)
10.1158/1078-0432.CCR-13-0895
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
M. Nishino (2013)
10.1200/jco.2014.32.18_suppl.lba9003
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
H. Kluger (2014)
10.1126/science.1202947
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
O. Qureshi (2011)
10.1186/1479-5876-10-146
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
W. Wang (2012)
10.1093/annonc/mdt107
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S. Slovin (2013)
10.1200/JCO.2014.32.15_SUPPL.3064
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.
C. Heery (2014)
10.1093/annonc/mdt161
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
J. Wolchok (2013)
10.1200/JCO.2011.38.4032
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
10.1093/ANNONC/MDU438.34
LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
J. Weber (2014)
hancement of antitumor immunity by CTLA - 4 block
A vanElsas (1996)
10.1056/NEJMcpc1302332
Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.
R. Sullivan (2013)
10.1200/jco.2013.31.18_suppl.cra9007
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.
S. Lee (2013)
10.1172/JCI67313
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
L. Deng (2014)
10.1158/1078-0432.CCR-11-1823
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
P. A. Prieto (2012)
10.1200/JCO.2001.19.13.3210
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
K. Kelly (2001)
10.1200/JCO.2012.48.3685
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
P. Armand (2013)
10.1200/JCO.2013.31.15_SUPPL.3016
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph F. Grosso (2013)
10.1200/JCO.2014.32.15_SUPPL.2511
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).
I. Puzanov (2014)
10.4161/onci.28780
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
A. Grimaldi (2014)
10.1186/s40425-014-0035-z
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi (2014)
10.1097/CJI.0b013e31829fb7a2
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
D. Le (2013)
10.1016/J.IMMUNI.2007.05.016
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
10.1158/1078-0432.CCR-10-0569
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Y. Saenger (2008)
10.1200/JCO.2014.32.15_SUPPL.9029
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
I. Puzanov (2014)
10.1200/JCO.2013.31.15_SUPPL.3044
Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.
J. Infante (2013)
10.1200/JCO.2013.31.15_SUPPL.3000
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
R. Herbst (2013)
10.1200/JCO.2013.31.15_SUPPL.9052
Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma.
M. Postow (2013)



This paper is referenced by
10.1002/cpdd.251
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T‐Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients
Tong Zhu (2016)
10.1080/10799893.2019.1655050
Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma
Fengfei Sun (2019)
10.12659/MSM.907439
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
Jibin Li (2018)
10.5772/INTECHOPEN.81150
Immunotherapy for Treatment of Cancer
Aida Karachi (2018)
10.1111/cas.13193
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
Takahisa Shirahama (2017)
10.1007/s12094-019-02241-5
The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis
S.-Y. Zheng (2019)
10.1016/j.nmd.2018.11.012
Clinical spectrum of neuromuscular complications after immune checkpoint inhibition
A. Puwanant (2019)
10.1042/BSR20200459
Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
X. Li (2020)
10.3390/ijms19123793
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Mathieu Césaire (2018)
10.1016/J.CRITREVONC.2019.03.019
Immune check-point in glioblastoma multiforme.
F. De Felice (2019)
10.1016/j.hoc.2018.12.005
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M. Rizk (2019)
10.3390/ijms19051295
T Cell Calcium Signaling Regulation by the Co-Receptor CD5
C. M. T. Freitas (2018)
10.3389/fphar.2018.01050
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Xinyu Yan (2018)
10.1002/ijc.31147
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
M. Schubert (2018)
10.1111/bjh.13976
The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma
A. Rotolo (2016)
10.1016/j.ctrv.2018.04.004
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
J. Taieb (2018)
10.1016/j.pharmthera.2016.07.012
Antibody-drug conjugates: Current status and future perspectives.
Rémy Gébleux (2016)
CMAR_A_203156 4743..4756
S. Zhao (2019)
10.1158/1078-0432.CCR-19-0733
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Cai Zhang (2019)
10.1002/jcph.591
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lucy Lee (2016)
10.1186/s13045-015-0222-5
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
A. Lin (2015)
Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
Dai Liu (2018)
10.1007/s00280-019-03894-3
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
J. L. da Silva (2019)
10.1200/JCO.2016.71.6795
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
A. Apolo (2017)
10.1080/13543784.2017.1351545
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
A. Guazzelli (2017)
10.1101/151738
A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours
Jia-Ren Lin (2017)
10.3390/cancers12102946
Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers
Emmanuel Dollinger (2020)
10.3389/fimmu.2020.00140
Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets
Luise Müller (2020)
10.1016/j.cllc.2017.02.004
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
K. Takada (2017)
10.1042/CS20190772
p110δ PI3K as a therapeutic target of solid tumours.
Lydia Xenou (2020)
10.2174/1568026619666190904163524
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
W. Hoo (2019)
Upregulation of Cytotoxic T-Lymphocyte- Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer
Ali Ariafar (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar